Streetbeat News

Stock Prices

COIN

Financial giants have shown a bearish sentiment towards Coinbase Global (NASDAQ:COIN) with 48% of options trades being bearish. The stock is currently down by 4.96% at $181.74, and analysts have set an average target price of $169.0. Barclays upgraded its rating to Equal-Weight with a price target of $169.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 3:00 pm

TSM

The article provides a comprehensive comparison of Taiwan Semiconductor (TSMC) with its industry competitors, highlighting TSMC's strong market position, financial metrics, and growth prospects. TSMC shows potential undervaluation with a low P/E and P/B ratio, high profitability, and robust revenue growth, despite a high P/S ratio.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 3:00 pm

TSLA

The article evaluates Tesla (NASDAQ:TSLA) against its peers in the automobile industry, highlighting its high valuation metrics and lower profitability and growth potential compared to competitors. Despite a strong financial position with a low debt-to-equity ratio, Tesla's PE, PB, and PS ratios suggest overvaluation, while its ROE, EBITDA, gross profit, and revenue growth lag behind industry averages.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 3:00 pm

REGN

Regeneron Pharmaceuticals (NASDAQ:REGN) has significantly outperformed the market over the past 5 years, with an average annual return of 29.94%. A $100 investment in REGN 5 years ago would now be worth $373.39, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 3:00 pm

COP

In the past three months, 13 analysts have provided ratings for ConocoPhillips (NYSE:COP), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has decreased by 5.44% to $140.31. Analysts have adjusted their ratings and price targets in response to market conditions, with several lowering their targets. ConocoPhillips shows strong financial performance with impressive revenue growth, net margin, ROE, and ROA, despite facing challenges compared to peers.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 3:00 pm

ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY) has significantly outperformed the market over the past 15 years, with an annualized return of 18.47%. A $100 investment in ALNY 15 years ago would be worth $1,295.68 today. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 3:00 pm

MSFT

The article provides a comprehensive comparison of Microsoft (NASDAQ:MSFT) against its competitors in the software industry, focusing on financial metrics, market position, and growth prospects. Microsoft is highlighted as having a lower P/E and P/B ratio, indicating potential undervaluation, but a higher P/S ratio, suggesting possible overvaluation. Despite a lower ROE, Microsoft's strong EBITDA, gross profit, and revenue growth demonstrate robust profitability and market expansion. Additionally, Microsoft's lower debt-to-equity ratio indicates a stronger financial position compared to its peers.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 3:00 pm

CCAP

Crescent Capital BDC (NASDAQ:CCAP) has received mixed analyst ratings over the past three months, with a consistent average price target of $19. Analysts have varied in their ratings from 'Buy' to 'Equal-Weight', reflecting differing views on the company's performance. Despite a decline in revenue, Crescent Capital BDC shows strong profitability and financial health with high net margins and ROE.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 3:00 pm

DOGEUSD

Dogecoin's price has decreased by 4.8% in the last 24 hours to $0.12, despite a 12% gain over the past week. Trading volume increased by 50% over the week, with a circulating supply of 146.13 billion. Dogecoin's market cap is ranked #9 at $17.44 billion.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 3:00 pm

CAPR

LI

MNSO

NIO

PRME

TIGR

UXIN

WB

Prime Medicine's stock surged 39.6% after announcing a collaboration with Bristol Myers Squibb. Other notable gainers include Uxin Limited, UP Fintech, Capricor Therapeutics, and several US-listed Chinese companies like NIO and Li Auto, driven by positive sentiment from Chinese economic data.

Portfolio Pulse from Avi Kapoor

September 30, 2024 | 2:58 pm